Initiated by and co-organised with Medicines for Europe, the Permanent Representation of Hungary hosted a Seminar on “The Supplementary Protection Certificate (SPC) Manufacturing Waiver: A Boost to Jobs & Growth in Europe” for industrial property attachés on 3 May. Besides the attachés of the different Permanent Representations, the representatives of the European Commission, the European Patent Office and a number of European pharmaceutical companies (TEVA, Mylan, Assogenerici, Fresenius Kabi) participated in the event. The Seminar was opened by Ambassador Tibor Stelbaczky, Deputy Permanent Representative of Hungary. The representative of the European Commission outlined the plans for the review and optimization of the industrial property legal framework for SPCs, while the pharmaceutical manufacturers illustrated the shortcomings of the current legislation by practical examples and highlighted the advantages of introducing an SPC Manufacturing Waiver. These advantages could be the most prominent as regards the promotion of economic growth, creation of jobs and avoiding the translocation of the manufacturing of pharmaceutical products outside the European Union.
